MyFinsight
Home
Blog
About
Issuance of shares,
options exercise
$1,961K
(954.30%↑ Y/Y)
Net income/(loss)
$1,973K
(145.70%↑ Y/Y)
Stock-based compensation
$1,774K
(-22.60%↓ Y/Y)
Other non-current
assets
-$1,664K
Other current assets
-$646K
Accrued liabilities
$639K
(153.12%↑ Y/Y)
Amortization of norgine asset
$25K
(-50.98%↓ Y/Y)
Net cash provided by
financing activities
$1,020K
(1260.00%↑ Y/Y)
Net cash provided
by/(used in) operating...
$50K
(100.62%↑ Y/Y)
Canceled cashflow
$941K
Canceled cashflow
$6,671K
Increase/(decrease) in cash and cash
equivalents
$1,070K
(113.49%↑ Y/Y)
Cash paid for taxes on
restricted share release
$941K
(747.75%↑ Y/Y)
Accounts receivable
$4,217K
(-23.91%↓ Y/Y)
Accounts payable
-$765K
(-128.33%↓ Y/Y)
Contract liability
-$710K
Inventory
$518K
(-54.60%↓ Y/Y)
Allowance for credit
losses
-$287K
(-123.49%↓ Y/Y)
Prepaid expenses
$174K
(-89.51%↓ Y/Y)
Back
Back
Cash Flow
FENNEC PHARMACEUTICALS INC. (FENC)
FENNEC PHARMACEUTICALS INC. (FENC)
source: myfinsight.com